Ventas (VTR)
(Delayed Data from NYSE)
$62.53 USD
-0.04 (-0.06%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $62.54 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.53 USD
-0.04 (-0.06%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $62.54 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Zacks News
Healthpeak (PEAK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
While higher occupancy levels at senior housing facilities are likely to have aided Healthpeak (PEAK) in Q3, large asset disposals might have been a deterrent.
What's in Store for W. P. Carey (WPC) This Earnings Season?
by Zacks Equity Research
While W. P. Carey's (WPC) Q3 results will reflect gains from its high-quality diversified portfolio and strategic investments, choppiness in certain real estate categories is a concern.
Factors to Impact Public Storage (PSA) This Earnings Season
by Zacks Equity Research
Public Storage's (PSA) results will likely reflect gains from high brand value and its solid presence in key cities, driving the occupancy level and rental rate hikes.
Key Factors to Impact Medical Properties' (MPW) Q3 Earnings
by Zacks Equity Research
Stellar revenues from transactions and improving fundamentals of its tenants are likely to have aided Medical Properties' (MPW) Q3 performance.
What's in the Offing for Arbor Realty (ABR) in Q3 Earnings?
by Zacks Equity Research
While lower prepayments and improving asset yields are expected to have aided, new agency loan originations in Q3 are likely to have expanded Arbor Realty's (ABR) fee-based servicing portfolio.
Here's How VICI Properties (VICI) is Placed Ahead of Q3 Earnings
by Zacks Equity Research
VICI Properties' (VICI) quarterly results will likely display growth in both revenues and funds from operations (FFO) per share.
Ventas (VTR) Concludes New Senior Investment Group Acquisition
by Zacks Equity Research
Ventas' (VTR) latest acquisition of New Senior Investment positions the healthcare REIT well to bank on the senior housing industry's recovery.
Ventas (VTR) Inches Closer to New Senior Investment Merger
by Zacks Equity Research
Ventas (VTR) moves closer toward its proposed merger of New Senior Investment Group with an approval of the latter's stockholders.
Here's Why You Should Hold Ventas (VTR) Stock in Your Portfolio
by Zacks Equity Research
While Ventas' (VTR) office segment and senior housing operations have upside potential, competition from national and local healthcare operators is a concern.
Ventas (VTR) Q2 FFO Tops Estimates, Senior Housing Occupancy Up
by Zacks Equity Research
Ventas' (VTR) Q2 results reflect sequential occupancy improvement in its Senior Housing Operating Portfolio segment as well as growth in the Office segment.
Ventas (VTR) Q2 FFO Beat Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 1.39% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
While Ventas (VTR) is well poised to bank on the senior housing industry's recovery that is likely to have aided it in Q2, disposition of assets and higher expenses might have been deterrents.
Chimera (CIM) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
While securitizations in the prior quarters are likely to have provided stable interest income for Chimera (CIM) in Q2, a challenging backdrop for Agency securities is likely to have hurt valuations.
Healthpeak (PEAK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
While life-science and medical office portfolios are likely to have aided Healthpeak (PEAK) in Q2, large asset disposals and lower occupancy levels at senior housing facilities are the headwinds.
Ventas (VTR) to Acquire New Senior Investment in $2.3B Deal
by Zacks Equity Research
Ventas' (VTR) deal to acquire New Senior Investment will poise the healthcare REIT well to capitalize on the senior housing industry's recovery and will likely be accretive to its FFO per share.
Ventas (VTR) Q1 FFO Beats, Senior Housing Occupancy Dips
by Zacks Equity Research
While Ventas' (VTR) office portfolio displays marginal net operating income growth, declining occupancy at its senior housing operating portfolio continues to be a deterrent in Q1.
Ventas (VTR) Tops Q1 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.86% and 1.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Lamar (LAMR) Beats Q1 Revenue Estimates, Raises 2021 View
by Zacks Equity Research
Lamar's (LAMR) Q1 results reflect higher-than-anticipated revenues. The REIT also raised its prior guidance for 2021 on anticipated continued recovery from the pandemic.
Ventas (VTR) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
While the gradual rebound in clinical activity is expected to have supported Ventas' (VTR) office segment performance, the pandemic-led concerns continued to be setbacks for its seniors housing business.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Is Recovery in the Cards for Welltower (WELL) in Q1 Earnings?
by Zacks Equity Research
Despite increased coverage of vaccine administration among senior housing residents, Welltower (WELL) witnesses a significant occupancy decline at its senior housing operating portfolio in Q1.
Life-Science Assets to Aid Ventas (VTR) Amid Pandemic Woes
by Zacks Equity Research
Amid the COVID-19 outbreak, which is taking a toll on Ventas' (VTR) senior housing operations, the company is attuning its portfolio with higher exposure to resilient office segment assets.
Welltower (WELL) Expects 1Q21 FFO to Reach Top-End of Outlook
by Zacks Equity Research
Backed by a rise in vaccination coverage, the removal of admission bans and a spike in move-ins, Welltower's (WELL) seniors housing occupancy decline moderated in March. This will aid Q1 results.
Ventas (VTR) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mack-Cali (CLI) Q4 FFO & Revenues Miss Estimates, NOI Declines
by Zacks Equity Research
Mack-Cali's (CLI) fourth-quarter results were hindered by the same-store cash revenue and net operating income declines in its office portfolio.